Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.820.896 €): Sensing und vorausschauende Behandlung von Gebrechlichkeit und damit verbundenen Komorbiditäten mit fortschrittlichen personalisierten Patientenmodellen und … Hor01.01.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Sensing und vorausschauende Behandlung von Gebrechlichkeit und damit verbundenen Komorbiditäten mit fortschrittlichen personalisierten Patientenmodellen und fortgeschrittenen Interventionen
Ageing population is steeply increasing worldwide. A consequence of age related decline is the clinical condition of frailty. Frailty is a biological syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems and causing vulnerability to adverse outcomes. Susceptibility to stressors is influenced by biological, behavioral, environmental, and social risk factors, with the main consequence being an increased risk for multiple adverse health outcomes, including disability, morbidity, falls, hospitalization, institutionalization, and death. However, frailty is a dynamic and not an irreversible process; it seems preventable, may be delayed, or reversed. Our understanding of frailty has markedly improved over the last five years, yet there are many issues yet to be resolved. FrailSafe aims to better understand frailty and its relation to co-morbidities; to identify quantitative and qualitative measures of frailty through advanced data mining approaches on multiparametric data and use them to predict short and long-term outcome and risk of frailty; to develop real life sensing (physical, cognitive, psychological, social) and intervention (guidelines, real-time feedback, AR serious games) platform offering physiological reserve and external challenges; to provide a digital patient model of frailty sensitive to several dynamic parameters, including physiological, behavioural and contextual; this model being the key for developing and testing pharmaceutical and non-pharmaceutical interventions; to create “prevent-frailty” evidence-based recommendations for the elderly; to strengthen the motor, cognitive, and other “anti-frailty” activities through the delivery of personalised treatment programmes, monitoring alerts, guidance and education; and to achieve all with a safe, unobtrusive and acceptable system for the ageing population while reducing the cost of health care systems.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Agecare (Cyprus) Ltd. | 252.500 € |
| AGE Platform Europe | 175.903 € |
| Brainstorm Multimedia SL | 321.250 € |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | 535.000 € |
| Gruppo Sigla Srl | 589.125 € |
| Hypertech (Chaipertek) Anonymos Viomichaniki Emporiki Etaireia Pliroforikis Kai Neon Technologion | 220.000 € |
| Institut National de la Sante et de la Recherche Medicale | 361.696 € |
| Panepistimio Patron | 831.000 € |
| Smartex Srl | 534.423 € |
Quelle: https://cordis.europa.eu/project/id/690140
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.